Phone: 1-800-748-7001. Monitor blood pressure in patients treated with Sumatriptan. Sumatriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. The exception is the $0 Deductible Plans.Please check the formulary for different brand and generic names. Limitations of Use: 1. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.A cardiovascular evaluation is recommended for geriatric patients who have other cardiovascular risk factors (e.g., diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving Sumatriptan tablets The maximum single dose in patients with mild to moderate hepatic impairment should not exceed 50 mg. Sumatriptan tablets are contraindicated in patients with severe hepatic impairment [see Clinical Pharmacology (12.3)].Patients in clinical trials (N = 670) received single oral doses of 140 to 300 mg without significant adverse reactions. Do not use Sumatriptan tablets for a condition for which they were not prescribed. Safety and effectiveness … In 1 trial, doses of 25, 50, and 100 mg were also compared with each other.In all 3 trials, the percentage of patients achieving headache response 2 and 4 hours after treatment was significantly greater among patients receiving Sumatriptan tablets at all doses compared with those who received placebo. In general, anaphylactic reactions to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens. In patients who experience symptoms or signs suggestive of non-coronary vasospasm reaction following the use of any 5-HTReports of transient and permanent blindness and significant partial vision loss have been reported with the use of 5‑HTOveruse of acute migraine drugs (e.g., ergotamine, triptans, opioids, or combination of these drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache). A study using linked data from the Medical Birth Registry of Norway to the Norwegian Prescription Database compared pregnancy outcomes in women who redeemed prescriptions for triptans during pregnancy, as well as a migraine disease comparison group who redeemed prescriptions for Sumatriptan before pregnancy only, compared with a population control group. 2. Only treatment-emergent adverse reactions that occurred at a frequency of 2% or more in any group treated with Sumatriptan tablets and that occurred at a frequency greater than the placebo group are included in Table 1. Below is your cost or co-pay for Sumatriptan Succinate in Mercer County West Virginia. The components of opadry yellow used in the formulation of 25 mg tablets are hypromellose, titanium dioxide, polyethylene glycol 6000, iron oxide yellow, and polysorbate 80. Higher doses may have a greater risk of adverse reactions If the migraine has not resolved by 2 hours after taking Sumatriptan tablets, or returns after a transient improvement, a second dose may be administered at least 2 hours after the first dose. Please check the formulary for different brand and generic drug names. Talk to your doctor first about changing your prescription to a drug on your plans formulary. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. NDC 42043-222-09Store at 20° to 25°C (68° and 77°F). Such reactions can be life-threatening or fatal. Acetaminophen was offered to patients in Trials 2 and 3 beginning at 2 hours after initial treatment if the migraine pain had not improved or had worsened. If this is not an option, you can request an exception to have the plan review its coverage decision based on your individual circumstances. There are also reports in patients where no such predisposing factors are apparent. If there is evidence of CAD or coronary artery vasospasm, Sumatriptan tablets are contraindicated. The incidence of adverse reactions in controlled clinical trials was not affected by gender or age of the patients. Available for Android and iOS devices. Defects in the corneal epithelium were noted in a 60 week study. The use of Sumatriptan tablets in this population is contraindicated Monoamine Oxidase-A Inhibitors:Treatment with MAO-A inhibitors generally leads to an increase of Sumatriptan plasma levels Due to gut and hepatic metabolic first-pass effects, the increase of systemic exposure after coadministration of an MAO-A inhibitor with oral Sumatriptan is greater than after coadministration of the MAO inhibitors with subcutaneous Sumatriptan.In a trial of 14 healthy females, pretreatment with an MAO-A inhibitor decreased the clearance of subcutaneous Sumatriptan, resulting in a 2 fold increase in the area under the Sumatriptan plasma concentration-time curve (AUC), corresponding to a 40% increase in elimination half-life.A small trial evaluating the effect of pretreatment with an MAO-A inhibitor on the bioavailability from a 25 mg oral Sumatriptan tablet resulted in an approximately 7 fold increase in systemic exposure.In carcinogenicity studies in mouse and rat, Sumatriptan was administered orally for 78 and 104 weeks, respectively, at doses up to 160 mg/kg/day (the high dose in rat was reduced from 360 mg/kg/day during Week 21).